{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T19:27:17Z","timestamp":1777836437832,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":175,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01LM013352-01A1"],"award-info":[{"award-number":["1R01LM013352-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We created a database of reconstructed patient-level data from published clinical trials that includes multiple time-to-event outcomes such as overall survival and progression-free survival. Outcomes were extracted from Kaplan\u2013Meier (KM) curves reported in 153 oncology Phase III clinical trial publications identified through a PubMed search of clinical trials in breast, lung, prostate and colorectal cancer, published between 2014 and 2016. For each trial that met our search criteria, we curated study-level information and digitized all reported KM curves with the software Digitizelt. We then used the digitized KM survival curves to estimate (possibly censored) patient-level time-to-event outcomes. Collections of time-to-event datasets from completed trials can be used to support the choice of appropriate trial designs for future clinical studies. Patient-level data allow investigators to tailor clinical trial designs to diseases and classes of treatments. Patient-level data also allow investigators to estimate the operating characteristics (e.g. power and type I error rate) of candidate statistical designs and methods.<\/jats:p><jats:p>Database URL: https:\/\/10.6084\/m9.figshare.14642247.v1<\/jats:p>","DOI":"10.1093\/database\/baab037","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T11:24:43Z","timestamp":1622114683000},"source":"Crossref","is-referenced-by-count":3,"title":["KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials"],"prefix":"10.1093","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6436-6691","authenticated-orcid":false,"given":"Geoffrey","family":"Fell","sequence":"first","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA"}]},{"given":"Robert A","family":"Redd","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA"}]},{"given":"Alyssa M","family":"Vanderbeek","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, Institute of Cancer Research, 123 Old Brompton Road, Sutton, London SW73RP, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9443-1797","authenticated-orcid":false,"given":"Rifaquat","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA"},{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, 450 Brookline Ave, Boston, MA 02215, USA"}]},{"given":"Bill","family":"Louv","sequence":"additional","affiliation":[{"name":"Project Data Sphere, 1204 Village Market Place, Suite 288, Morrisville, NC 27560, USA"}]},{"given":"Jon","family":"McDunn","sequence":"additional","affiliation":[{"name":"Project Data Sphere, 1204 Village Market Place, Suite 288, Morrisville, NC 27560, USA"}]},{"given":"Andrea","family":"Arf\u00e8","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA"},{"name":"Department of Radiation Oncology, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA"}]},{"given":"Brian M","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA"},{"name":"Department of Radiation Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, 450 Brookline Ave, Boston, MA 02215, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-9560","authenticated-orcid":false,"given":"Steffen","family":"Ventz","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA"}]}],"member":"286","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"2021070818444044100_R1","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-18-3999","article-title":"Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications","volume":"25","author":"Rahman","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2021070818444044100_R2","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-18-3999","article-title":"Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications","volume":"25","author":"Rahman","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2021070818444044100_R3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1377\/hlthaff.2017.1579","article-title":"Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study","volume":"37","author":"Agarwala","year":"2018","journal-title":"Health Aff."},{"key":"2021070818444044100_R4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"2021070818444044100_R5","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1158\/1078-0432.CCR-19-0820","article-title":"Design and evaluation of an external control arm using prior clinical trials and real-world data","volume":"25","author":"Ventz","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2021070818444044100_R6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21116-4","article-title":"The effects of releasing early results from ongoing clinical trials","volume":"12","author":"Ventz","year":"2021","journal-title":"Nat. Commun."},{"key":"2021070818444044100_R7","doi-asserted-by":"publisher","DOI":"10.1111\/biom.13315","article-title":"Optimality of testing procedures for survival data in the nonproportional hazards setting","author":"Arf\u00e8","year":"2020","journal-title":"Biometrics"},{"key":"2021070818444044100_R8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMc1716612","article-title":"Hazards of hazard ratios-deviations from model assumptions in immunotherapy","volume":"378","author":"Alexander","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021070818444044100_R9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"2021070818444044100_R10","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2011.39.8420","article-title":"Bayesian adaptive randomized trial design for patients with recurrent glioblastoma","volume":"30","author":"Trippa","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2021070818444044100_R11","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1158\/1078-0432.ccr-19-0945","article-title":"Lessons learned from de-escalation trials in favorable risk HPV-associated squamous cell head and neck cancer - a perspective on future trial designs","volume":"25","author":"Ventz","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2021070818444044100_R12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00060","article-title":"CancerLin Q: origins, implementation, and future directions","volume":"2","author":"Rubinstein","year":"2018","journal-title":"JCO Clin Cancer Inform."},{"key":"2021070818444044100_R13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMp1607342","article-title":"The Yale Open Data Access (YOD) project \u2014 a mechanism for data sharing","volume":"375","author":"Krumholz","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021070818444044100_R14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon-2017-0521","article-title":"Using oncology real-world evidence for quality improvement and discovery: the case for ASCO\u2019s CancerLinQ","volume":"14","author":"Miller","year":"2018","journal-title":"Future Oncol."},{"key":"2021070818444044100_R15","doi-asserted-by":"crossref","DOI":"10.1201\/b18041","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"2015","edition":"3rd"},{"key":"2021070818444044100_R16","volume-title":"(software)"},{"key":"2021070818444044100_R17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"2021070818444044100_R18","first-page":"1","article-title":"A language and environment for statistical computing","volume":"2","author":"R-Core-Team","year":"2018","journal-title":"R Found Stat. Comput."},{"key":"2021070818444044100_R19","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB\/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal","volume":"26","author":"Yoshioka","year":"2015","journal-title":"Ann. Oncol."},{"key":"2021070818444044100_R20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1634\/theoncologist.2014-0431","article-title":"The project data sphere initiative: accelerating cancer research by sharing data","volume":"20","author":"Green","year":"2015","journal-title":"Oncologist"},{"key":"2021070818444044100_R21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2021070818444044100_R22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"2021070818444044100_R23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"A language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J. Comput. Graph Stat."}],"container-title":["Database"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab037\/38828322\/baab037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baab037\/38828322\/baab037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T17:17:51Z","timestamp":1725124671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/database\/article\/doi\/10.1093\/database\/baab037\/6309184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1093\/database\/baab037","relation":{},"ISSN":["1758-0463"],"issn-type":[{"value":"1758-0463","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"baab037"}}